JACOBSON PHARMA

Jacobson Pharma consolidated today amid thin trading activity, with the stock declining to HK$1.030 in the morning session before rebounding to HK$1.060 in the afternoon and closing at HK$1.050. Looking at latest financial results, Q4 revenue reached HK$401.5 million, up 4.7% year-over-year, but operating profit contracted 11.52% and net profit fell 0.6%, signaling underlying profitability pressure. Net profit margin remained solid at 19.88%. Valuation metrics appear attractive: PE trades at just 6.96x with PB of only 0.91x well below book value, while offering a 4.05% dividend yield. Regarding price positioning, the stock has declined 18.6% year-to-date and fallen 32.69% from its 52-week high of HK$1.56, now approaching 52-week lows near HK$0.98 at compressed valuations. While market sentiment reflects skepticism about growth, the deeply discounted valuation may be providing meaningful price support.

Jacobson Pharma (2633.HK) gained 0.49% to HK$1.030 today, reaching an intraday high of HK$1.040 at 09:45 before a pullback in the afternoon. Trading volume was exceptionally thin at 142,000 shares with 0.1% turnover. Fundamentally, Q4 operating profit declined 11.52% year-on-year despite 4.7% revenue growth, with EPS down 1.17%, signaling margin pressure. The current PE of 6.83 and PB of 0.89 suggest depressed valuation, yet the stock has tumbled 20.16% year-to-date to HK$1.030, sitting 33.97% below its 52-week high of HK$1.56 and merely 5.1% above the 52-week low of HK$0.98. This stark divergence between valuation metrics and price action reflects investor skepticism about near-term prospects. Recent developments lack positive catalysts, with board adjustments and portfolio changes qualifying as routine matters. While depressed valuations offer theoretical downside protection, extreme illiquidity and underlying margin compression remain key headwinds.

The stock closed at HK$1.025, down 0.49% from the previous close, as the morning session saw zero trading activity while the afternoon session touched a high of HK$1.045 before retreating, with extremely thin liquidity (zero turnover rate, only 28,000 shares traded), reflecting weak market interest and severe liquidity constraints. On the fundamentals, FY2026 results showed operating revenue growth of 4.7% to HK$401.5 million, but operating profit declined 11.52% and net profit slipped 0.6%, signaling weaker earnings momentum. The stock has fallen 20.54% year-to-date and is down 35.94% from its 52-week high of HK$1.6, trading below both the 20-day moving average of HK$1.058 and 60-day moving average of HK$1.075. Valuations appear compressed with a PE of just 6.8x and a PB of 0.89 trading below book value, though the dividend yield stands at 4.15%. The company's subsidiary recently acquired a 24.9% stake in Li Chung Shing Tong for HK$74.7 million to expand herbal medicine operations; however, profit pressures and limited liquidity remain key headwinds.

The stock closed at HK$1.03, down 0.5% today, primarily driven by a continuation of year-to-date technical weakness—while full-year revenue grew 4.7% to HK$401.5m, operating profit fell 11.5% to HK$101.9m, and this earnings headwind combined with cautious sentiment extended the year-to-date decline to over 20%. The stock now trades near 52-week lows of HK$0.98, down 38% from the 52-week high of HK$1.66, trading well below the 20-day moving average of 1.06 and 60-day moving average of 1.078. Intraday action showed the stock opening at 1.04 in the morning session and gradually weakening to touch intraday lows near 1.025 in the afternoon before settling around 1.03; turnover of HK$66.3m reflected muted trading activity. Valuation metrics now appear relatively attractive: PB has fallen to 0.89 (below book value), PE stands at a compressed 6.83, and the dividend yield reaches 4.13%, all at historically attractive levels. Recent management moves including the appointment of an independent director and the release of the annual report reflect ongoing governance enhancements.

The stock declined about 1% today, falling from 1.045 to 1.035, primarily due to thin trading volume and consolidation pressure following the substantial prior decline. Trading commenced in the afternoon session at 1 PM, briefly touching 1.050 before closing lower. Year-to-date, the stock has retreated 19.77%, and it has fallen 38.02% from the 52-week high of 1.67 recorded in August 2025; the current price trades meaningfully below both the 20-day and 60-day moving averages of 1.063 and 1.079 respectively. Recent quarterly results show revenue growth of 4.7% to HK$401 million, though net profit declined 0.6% to HK$79.8 million, maintaining a net margin of 19.88%. Valuations appear compressed at a P/E of 6.86 and P/B of 0.89, yet the slowing revenue momentum and profit contraction, combined with recent management changes and a HK$600 million Tai Po facility investment, suggest lingering caution in the market's outlook and continued soft trading activity.